Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Tissue Selection and Nucleic Acid Extraction
4.3. Sequencing Panel, Library Preparation, and Template Preparation
4.4. Data Analysis
4.5. Statistical Analysis
4.6. Lollipop Plot
4.7. Access to Publicly Available Genomic Data
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
- Başaran, G.A.; Twelves, C.; Diéras, V.; Cortés, J.; Awada, A. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat. Rev. 2018, 63, 144–155. [Google Scholar] [CrossRef]
- Redig, A.J.; McAllister, S.S. Breast cancer as a systemic disease: A view of metastasis. J. Intern. Med. 2013, 274, 113–126. [Google Scholar] [CrossRef]
- Sledge, G.W.J.; Toi, M.; Neven, P.; Sohn, J.; Inoue, K.; Pivot, X.; Burdaeva, O.; Okera, M.; Masuda, N.; Kaufman, P.A.; et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020, 6, 116–124. [Google Scholar] [CrossRef]
- Mariotto, A.B.; Etzioni, R.; Hurlbert, M.; Penberthy, L.; Mayer, M. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiol. Biomark. Prev. 2017, 26, 809–815. [Google Scholar] [CrossRef] [PubMed]
- Mehta, R.S.; Barlow, W.E.; Albain, K.S.; Vandenberg, T.A.; Dakhil, S.R.; Tirumali, N.R.; Lew, D.L.; Hayes, D.F.; Gralow, J.R.; Linden, H.H.; et al. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. N. Engl. J. Med. 2019, 380, 1226–1234. [Google Scholar] [CrossRef]
- Sánchez, C.; Domínguez, F.; Galindo, H.; Camus, M.; Oddo, D.; Villarroel, A.; Razmilic, D.; Peña, J.; Navarro, M.E.; Medina, L.; et al. Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases. Rev. Med. Chile 2020, 148, 1233–1238. [Google Scholar] [CrossRef] [PubMed]
- Koboldt, D.C.; Fulton, R.S.; McLellan, M.D.; Schmidt, H.; Kalicki-Veizer, J.; McMichael, J.F.; Fulton, L.L.; Dooling, D.J.; Ding, L.; Mardis, E.R.; et al. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70. [Google Scholar]
- Jenkins, M.L.; Ranga-Prasad, H.; Parson, M.A.H.; Harris, N.J.; Rathinaswamy, M.K.; Burke, J.E. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. Nat. Commun. 2023, 14, 181. [Google Scholar] [CrossRef]
- Bader, A.G.; Kang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 2005, 5, 921–929. [Google Scholar] [CrossRef]
- US Food and Drugs Administration. FDA Approves Alpelisib for Metastatic Breast Cancer. 2019. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer (accessed on 5 November 2024).
- André, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H.S.; Iwata, H.; Conte, P.; Mayer, I.A.; Kaufman, B.; et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 2019, 380, 1929–1940. [Google Scholar] [CrossRef] [PubMed]
- Lefebvre, C.; Bachelot, T.; Filleron, T.; Pedrero, M.; Campone, M.; Soria, J.-C.; Massard, C.; Lévy, C.; Arnedos, M.; Lacroix-Triki, M.; et al. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med. 2016, 13, e1002201. [Google Scholar] [CrossRef] [PubMed]
- Bertucci, F.; Ng, C.K.Y.; Patsouris, A.; Droin, N.; Piscuoglio, S.; Carbuccia, N.; Soria, J.C.; Dien, A.T.; Adnani, Y.; Kamal, M.; et al. Genomic characterization of metastatic breast cancers. Nature 2019, 569, 560–564. [Google Scholar] [CrossRef] [PubMed]
- Angus, L.; Smid, M.; Wilting, S.M.; van Riet, J.; Van Hoeck, A.; Nguyen, L.; Nik-Zainal, S.; Steenbruggen, T.G.; Tjan-Heijnen, V.C.G.; Labots, M.; et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet. 2019, 51, 1450–1458. [Google Scholar] [CrossRef]
- Tao, Z.; Li, T.; Feng, Z.; Liu, C.; Shao, Y.; Zhu, M.; Gong, C.; Wang, B.; Cao, J.; Wang, L.; et al. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. Front. Oncol. 2020, 10, 1023. [Google Scholar] [CrossRef]
- Meric-Bernstam, F.; Zheng, X.; Shariati, M.; Damodaran, S.; Wathoo, C.; Brusco, L.; Demirhan, M.E.; Tapia, C.; Eterovic, A.K.; Basho, R.K.; et al. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis. Oncol. 2018; Epub ahead of print. [Google Scholar] [CrossRef]
- Schleifman, E.B.; Desai, R.; Spoerke, J.M.; Xiao, Y.; Wong, C.; Abbas, I.; O’Brien, C.; Patel, R.; Sumiyoshi, T.; Fu, L.; et al. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS ONE 2014, 9, e88401. [Google Scholar] [CrossRef]
- Fumagalli, D.; Wilson, T.R.; Salgado, R.; Lu, X.; Yu, J.; O’Brien, C.; Walter, K.; Huw, L.Y.; Criscitiello, C.; Laios, I.; et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Ann. Oncol. 2016, 27, 1860–1866. [Google Scholar] [CrossRef] [PubMed]
- Kingston, B.; Cutts, R.J.; Bye, H.; Beaney, M.; Walsh-Crestani, G.; Hrebien, S.; Swift, C.; Kilburn, L.S.; Kernaghan, S.; Moretti, L.; et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat. Commun. 2021, 12, 2423. [Google Scholar] [CrossRef]
- Rugo, H.S.; Raskina, K.; Schrock, A.B.; Madison, R.W.; Graf, R.P.; Sokol, E.S.; Sivakumar, S.; Lee, J.K.; Fisher, V.; Oxnard, G.R.; et al. Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma. Clin. Cancer Res. 2023, 29, 1056–1067. [Google Scholar] [CrossRef]
- Suppan, C.; Graf, R.; Jahn, S.; Zhou, Q.; Klocker, E.V.; Bartsch, R.; Terbuch, A.; Kashofer, K.; Regitnig, P.; Lindenmann, J.; et al. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. Br. J. Cancer 2022, 126, 456–463. [Google Scholar] [CrossRef]
- Reinert, T.; do Rego, F.O.; Silva, M.C.E.; Rodrigues, A.M.; Koyama, F.C.; Gonçalves, A.C.; Pauletto, M.M.; de Carvalho Oliveira, L.J.; de Resende, C.A.A.; Landeiro, L.C.G.; et al. The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients. Front. Oncol. 2024, 14, 1372947. [Google Scholar] [CrossRef] [PubMed]
- Park, Y.H.; Im, S.-A.; Park, K.; Wen, J.; Lee, K.-H.; Choi, Y.-L.; Lee, W.-C.; Min, A.; Bonato, V.; Park, S.; et al. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. Genome Med. 2023, 15, 55. [Google Scholar] [CrossRef] [PubMed]
- Kindt, C.K.; Alves, C.L.; Ehmsen, S.; Kragh, A.; Reinert, T.; Vogsen, M.; Kodahl, A.R.; Rønlev, J.D.; Ardik, D.; Sørensen, A.L.; et al. Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer. Int. J. Cancer 2024, 155, 2211–2222. [Google Scholar] [CrossRef]
- Cordova-Delgado, M.; Pinto, M.P.; Regonesi, C.; Cereceda, L.; Reyes, J.M.; Itriago, L.; Majlis, A.; Rodríguez, P.; Fassler, A.; Mahave, M.; et al. Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience. J. Pers. Med. 2022, 12, 195. [Google Scholar] [CrossRef]
- Wagle, N.; Painter, C.; Anastasio, E.; Dunphy, M.; McGillicuddy, M.; Kim, D.; Jain, E.; Buendia-Buendia, J.; Cohen, O.; Knelson, E.; et al. The Metastatic Breast Cancer (MBC) project: Accelerating translational research through direct patient engagement. J. Clin. Oncol. 2024, 35, 1076. [Google Scholar] [CrossRef]
- Nik-Zainal, S.; Davies, H.; Staaf, J.; Ramakrishna, M.; Glodzik, D.; Zou, X.; Martincorena, I.; Alexandrov, L.B.; Martin, S.; Wedge, D.C.; et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 2016, 534, 47–54. [Google Scholar] [CrossRef] [PubMed]
- Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N.T.; Prat, A.; Chae, Y.S.; et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N. Engl. J. Med. 2022, 387, 9–20. [Google Scholar] [CrossRef]
- Li, H.; Wu, Y.; Zou, H.; Koner, S.; Plichta, J.K.; Tolaney, S.M.; Zhang, J.; He, Y.-W.; Wei, Q.; Tang, L.; et al. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: A secondary analysis of PALOMA-2 and PALOMA-3 trials. EBioMedicine 2024, 105, 105186. [Google Scholar] [CrossRef]
- Gampenrieder, S.P.; Rinnerthaler, G.; Tinchon, C.; Petzer, A.; Balic, M.; Heibl, S.; Schmitt, C.; Zabernigg, A.F.; Egle, D.; Sandholzer, M.; et al. Landscape of HER2-low metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry. Breast Cancer Res. 2021, 23, 112. [Google Scholar] [CrossRef]
- Holthuis, E.I.; Vondeling, G.T.; Kuiper, J.G.; Dezentjé, V.; Rosenlund, M.; Overbeek, J.A.; van Deurzen, C.H.M. Real-world data of HER2-low metastatic breast cancer: A population based cohort study. Breast 2022, 66, 278–284. [Google Scholar] [CrossRef]
- Vidal, M.; Rivera, A.; Schuler, C.; Garnham, N.; Alcalde, E.; Ahumada, P.P.; Renner, A. Frequency of HER2-Low in breast cancer biopsies in Chile. J. Clin. Oncol. 2024, 42, e13163. [Google Scholar] [CrossRef]
- Martínez-Cannon, B.A.; Verduzco-Aguirre, H.C. Frequency and prognosis of HER2-low status in Mexican patients with metastatic breast cancer. Cancer Res. 2023, 83, P3-05-58. [Google Scholar] [CrossRef]
- Calderón-Aparicio, A.; Orue, A. Precision oncology in Latin America: Current situation, challenges and perspectives. Ecancermedicalscience 2019, 13, 920. [Google Scholar] [CrossRef] [PubMed]
- Ruiz, R.; Strasser-Weippl, K.; Touya, D.; Herrero Vincent, C.; Hernandez-Blanquisett, A.; St Louis, J.; Bukowski, A.; Goss, P.E. Improving access to high-cost cancer drugs in Latin America: Much to be done. Cancer 2017, 123, 1313–1323. [Google Scholar] [CrossRef] [PubMed]
- Moye-Holz, D.; Vogler, S. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America. Appl. Health Econ. Health Policy 2022, 20, 67–77. [Google Scholar] [CrossRef]
- Madden, E.B.; Hindorff, L.A.; Bonham, V.L.; Akintobi, T.H.; Burchard, E.G.; Baker, K.E.; Begay, R.L.; Carpten, J.D.; Cox, N.J.; Di Francesco, V.; et al. Advancing genomics to improve health equity. Nat. Genet. 2024, 56, 752–757. [Google Scholar] [CrossRef]
- Alarcón Garavito, G.A.; Moniz, T.; Déom, N.; Redin, F.; Pichini, A.; Vindrola-Padros, C. The implementation of large-scale genomic screening or diagnostic programmes: A rapid evidence review. Eur. J. Hum. Genet. 2023, 31, 282–295. [Google Scholar] [CrossRef]
- Pawluk, A.; Alkuraya, F.; Liu, J. National Efforts with Global Implications. Cell 2019, 177, 16–19. [Google Scholar]
- Kokkat, T.J.; Patel, M.S.; McGarvey, D.; LiVolsi, V.A.; Baloch, Z.W. Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. Biopreserv. Biobank. 2013, 11, 101–106. [Google Scholar] [CrossRef]
- Allison, K.H.; Hammond, M.E.H.; Dowsett, M.; McKernin, S.E.; Carey, L.A.; Fitzgibbons, P.L.; Hayes, D.F.; Lakhani, S.R.; Chavez-MacGregor, M.; Perlmutter, J.; et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J. Clin. Oncol. 2020, 38, 1346–1366. [Google Scholar] [CrossRef]
- Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404. [Google Scholar] [CrossRef] [PubMed]
- Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, pl1. [Google Scholar] [CrossRef] [PubMed]
N = 96 Patients | N = 102 Samples | % | ||
---|---|---|---|---|
Age at stage IV dg (years) | <50 | 25 | 26 | |
≥50 | 65 | 67.7 | ||
Unknown | 6 | 6.3 | ||
Stage IV at diagnosis | Yes | 23 | 24 | |
No | 68 | 70.8 | ||
Unknown | 5 | 5.2 | ||
Metastatic site | Liver | 30 | 29.4 | |
Bone | 18 | 17.6 | ||
Lung/Pleura | 17 | 16.7 | ||
Soft tissue | 13 | 12.7 | ||
Skin | 9 | 8.8 | ||
Other | 15 | 14.7 | ||
Metastatic IHC pattern | HR+, HER2− | 80 | 85 | 83.3/83.3 |
HR+, HER2+ | 6 | 6 | 6.3/5.9 | |
HR−, HER2− | 6 | 7 | 6.3/6.9 | |
HR−, HER2+ | 4 | 4 | 4.2/3.9 | |
Breakdown HER2-IHC | HER2-low | 55 | 61 | 57.3/59.8 |
HER2-ultralow | 18 | 18 | 18.8/17.6 | |
HER2 status only | 13 | 13 | 13.5/12.7 | |
PIK3CA mutations | Exon 1 | 2 | 2 | 2.1/2 |
Exon 4 | 3 | 3 | 3.1/2.9 | |
Exon 7 | 2 | 2 | 2.1/2 | |
Exon 9 | 14 | 15 | 14.9/14.7 | |
Exon 20 | 16 | 16 | 16.7/15.7 | |
Exon 7 + 9 | 1 | 1 | 1/1 | |
Exon 7 + 20 | 1 | 1 | 1/1 | |
Exon 9 + 13 | 1 * | 1 | 1/1 | |
Total mutated | 39 | 41 | 40.6/40.2 | |
Metastatic follow-up (months) | Median | 28.7 | ||
Range | 0.3–181.3 |
PIK3CA-MUT | PIK3CA-WT | p-Value | ||
---|---|---|---|---|
Age at stage IV dg (years) | <50 | 10 | 15 | 0.8 |
≥50 | 28 | 37 | ||
Stage IV at diagnosis | Yes | 9 | 14 | 0.8 |
No | 29 | 39 | ||
Metastatic site | Liver | 14 | 13 | 0.2 |
Bone | 8 | 10 | ||
Lung/Pleura | 3 | 12 | ||
Soft tissue | 5 | 9 | ||
HER2 status | HER2-low | 20 | 35 | 0.2 |
HER2-ultralow | 10 | 8 |
Total Patients | Metastatic Sites (%) | PIK3CA Mutated (%) | Exons Involved (%) | |
---|---|---|---|---|
Araya et al. | 96 | Liver (29.4) | 39 (40.6) | Exon 1 (5.1) |
Bone (17.6) | Exon 4 (7.7) | |||
Lung/pleura (16.7) | Exon 7 (5.1) | |||
Exon 9 (38.5) | ||||
Exon 20 (41) | ||||
MBC Project | 70 | Liver (35.7) | 19 (27.1) | Exon 1 (5.3) |
Bone (68.6) | Exon 9 (57.9) | |||
Lung/pleura (31.4) | Exon 20 (36.8) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Araya, C.; Mino, B.; Le Cerf, P.; Gaete, F.; Armisen, R.; Carvajal-Hausdorf, D.E. Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights. Int. J. Mol. Sci. 2024, 25, 12246. https://doi.org/10.3390/ijms252212246
Araya C, Mino B, Le Cerf P, Gaete F, Armisen R, Carvajal-Hausdorf DE. Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights. International Journal of Molecular Sciences. 2024; 25(22):12246. https://doi.org/10.3390/ijms252212246
Chicago/Turabian StyleAraya, Carla, Bárbara Mino, Patricio Le Cerf, Fancy Gaete, Ricardo Armisen, and Daniel E. Carvajal-Hausdorf. 2024. "Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights" International Journal of Molecular Sciences 25, no. 22: 12246. https://doi.org/10.3390/ijms252212246
APA StyleAraya, C., Mino, B., Le Cerf, P., Gaete, F., Armisen, R., & Carvajal-Hausdorf, D. E. (2024). Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights. International Journal of Molecular Sciences, 25(22), 12246. https://doi.org/10.3390/ijms252212246